Bio-Techne Corporation TECH reported adjusted earnings per share (EPS) of 44 cents for the first quarter of fiscal 2027, up 4.8% year over year. The figure surpassed the Zacks Consensus Estimate by 10%.
The quarter's adjustments excluded amortization of intangible assets, acquisition-related expenses, stock-based compensation, restructuring costs and certain litigation charges, among others. GAAP EPS was 18 cents compared with 24 cents in the prior-year quarter.
TECH's Revenues in Detail
Net sales totaled $299.7 million, up 5% year over year on a reported basis and 7% on an organic basis. The figure surpassed the Zacks Consensus Estimate by 2.3%. Foreign currency had an immaterial impact, while a business held for sale had an unfavorable impact of 2%.
Consumables revenues increased 2.4% year over year to $237.3 million, while instrument revenues rose 16.8% to $25.5 million. Services revenues declined 18.3% to $22.5 million. Royalty revenues surged to $14.5 million from $5.6 million in the year-ago period.
Bio-Techne's Protein Sciences Sales Rise
Within Protein Sciences, Bio-Techne recorded revenues of $219.7 million, up 9% year over year from $202.2 million. Organic revenues also increased 9%, while foreign currency had an immaterial impact.
The segment's operating margin contracted 50 basis points (bps) to 37.9% from 38.4% in the prior-year quarter. Segment operating income increased to $83.2 million from $77.7 million a year ago, reflecting higher sales despite the narrower margin.
TECH's Diagnostics and Spatial Biology Performance
Within Diagnostics and Spatial Biology, revenues totaled $80.2 million, increasing 1% year over year from $79.5 million. Organic revenues also grew 1%, with foreign currency having an immaterial impact.
The segment's operating margin contracted 380 bps to 7.4% from 11.2% in the prior-year quarter. Segment operating income declined to $5.9 million from $8.9 million, reflecting weaker profitability despite modest revenue growth.
Bio-Techne Corp Price, Consensus and EPS Surprise
Bio-Techne Corp price-consensus-eps-surprise-chart | Bio-Techne Corp Quote
TECH's Expected Merger With Merck KGaA
In June 2026, Merck KGaA, Darmstadt, Germany, entered into a definitive agreement to acquire Bio-Techne Corporation for $73 per share in cash. The transaction values Bio-Techne at an enterprise value of approximately $11.3 billion, representing a 36% premium to its one-month volume-weighted average trading price. The acquisition is subject to customary closing conditions.
The deal brings together two complementary life sciences companies, strengthening their ability to serve customers across the entire life sciences value chain, from discovery and translational research to development, testing and commercial manufacturing. The merger is expected to strengthen its global presence and create a more connected organization across North America, Europe and Asia-Pacific, while providing employees with greater opportunities for collaboration and professional development.
Per the latest update, Bio-Techne shareholders approved and adopted the merger agreement with Merck KGaA at a special shareholders' meeting, marking an important step toward completing the acquisition. The transaction is expected to be closed by late 2026 or early 2027, subject to the satisfaction of customary closing conditions.
Our Take
Bio-Techne exited the fiscal first quarter with better-than-expected results, wherein both earnings and revenues beat estimates. Both the business segments posted revenue growth.
Instead of issuing a traditional earnings press release, the company disclosed its quarterly results in its Form 10-Q filing.
Zacks Rank & Other Stocks to Consider
TECH currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Medpace MEDP and GE HealthCare Technologies GEHC.
Intuitive Surgical, carrying a Zacks Rank #2 at present, posted third-quarter 2026 adjusted EPS of $3.00, exceeding the Zacks Consensus Estimate by 14.94%. Revenues of $3.05 billion topped the Zacks Consensus Estimate by 5.84%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an earnings yield of 2.5% against the industry’s negative 2.1% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 15.12%.
Medpace, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $4.84, which surpassed the Zacks Consensus Estimate by 8.76%. Revenues of $716 million beat the Zacks Consensus Estimate by 1.02%.
MEDP has an estimated long-term earnings growth rate of 14.3% compared with the industry’s 13.2%. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 9.77%.
GE HealthCare, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $1.34, which topped the Zacks Consensus Estimate by 10.74%. Revenues of $5.51 billion beat the Zacks Consensus Estimate by 2.87%.
GEHC has an earnings yield of 6.5% compared with the industry’s 2.8%. The company beat earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.15%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bio-Techne Corp (TECH): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report
GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).